Bluechiip secures $1 million deal with US customer
Bluechiip Limited (ASX:BCT), a growing developer of tracking technology, has secured an operational boost in the form of a $1 million sales deal, signed with an unnamed licensed Original Equipment Manufacturer (OEM) partner in the US.
Bluechiip says the OEM manufacturer has “placed orders for Bluechiip chips, readers, software and services valued at over A$1 million” and was completed to help Bluechiip “address a variety of markets in Life Sciences including cryogenics, drug screening, cell therapy as well as forensics”.
Speaking to Open Briefing, an Australian online investor communication platform, Bluechiip Managing Director Andrew McLellan says he’s guiding the company into a very large addressable market despite it being a niche at this early stage. “The revenue potential for Bluchiip in biobanking is over US$200m-US$300m per annum with significant room for growth.
“We have sold developer kits to 16 organisations, which is the pre-cursor step to OEM negotiations. We have also converted three of these developer kit sales into OEM agreements and we continue negotiations to convert several of our developer kit clients into OEM partners across multiple markets. Our cash receipts are growing at an accelerating rate now that we are entering the sales and production ramp phase,” he adds.
It should be noted that BCT is a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.
Bluchiip’s cash receipts for Q3 2017 were up 40% compared to last quarter and almost treble compared to the same time last year. “We expect growth to accelerate underpinned by the $1 million order we announced earlier this week,” says McLellan. “Over the next twelve months we expect to see products enter the market through product launches from our OEM partners and hopefully, an increase in the number of our own product orders.”
The $1 million deal signed this week, is expected to harness Bluechiip-enabled consumables to address a variety of markets in Life Sciences including cryogenics, drug screening, cell therapy as well as forensics. The deal also means Bluechiip will supply its US-based OEM-partner with chips, readers and software, all of which are either in production or progressing to production.
“Our sales growth numbers validate the partnering strategy we implemented two years ago. In 2015, Bluchiip was entering the market with our own vials and readers and at that point we only had a single point reader. We were attempting to compete in a very competitive bio-storage market. We changed the strategy and model to utilize our core capability and differentiator, our very unique Bluechiip technology, and partner through OEM agreements to access multiple global markets with global organizations.
“This strategy has been successful in enabling our products to differentiate themselves as well as helping us [Bluechiip] upscale our operations.”
More about Bluechiip Limited
Bluechiip was founded in 2002 and listed on the ASX in 2011. The company has its main head office in Melbourne, Australia, and is in the process of growing its operations globally via a series of distribution channels around the globe.
Bluechiip’s unique and patented technology combines secure wireless sample tracking with integrated temperature reading for use in extreme environments, working reliably in temperatures from -196°C to +200°C, and impervious to autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
Based on MEMS technology, the Bluechiip tag contains no electronics. Unlike traditional tracking technology like labels, barcodes or RFID, Bluechiip does not require line-of-sight visibility for temperature readings and tracking, and so can be read through frost without damaging the sample.
The tag can either be embedded or manufactured into storage products such as vials or bags. Easy identification, along with any associated information from the tag can be detected by a reader, which can also sense the temperature of the tagged items. Unlike other tracking methods, the Bluechiip technology can sense the temperature of each item a tag is attached to or embedded in.
This technology is particularly important for industries such as the $2b biopreservation & cryopreservation market, which processes more than 300 million samples per year of tissue, blood, serum, plasma, etc., for industries such as pharmaceuticals, IVF, research and clinical trials. It also has applications in cold chain logistics, food, manufacturing, security and defence.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.